235 related articles for article (PubMed ID: 29785232)
1. Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study.
Zhang X; Zhang X; Wang S; Luo J; Zhao Z; Zheng C; Shen J
Can Respir J; 2018; 2018():3148259. PubMed ID: 29785232
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.
Xiao JW; Zhu XY; Wang QG; Zhang DZ; Cui CS; Zhang P; Chen HY; Meng LL
Circ J; 2015; 79(6):1342-8. PubMed ID: 25797071
[TBL] [Abstract][Full Text] [Related]
3. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.
Li F; Xia W; Yuan S; Sun R
Pediatr Cardiol; 2009 Apr; 30(3):363-6. PubMed ID: 18953591
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Dai ZK; Wu BN; Chen IC; Chai CY; Wu JR; Chou SH; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2011 Jan; 46(1):45-59. PubMed ID: 20717937
[TBL] [Abstract][Full Text] [Related]
5. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction.
Andersen MJ; Hwang SJ; Kane GC; Melenovsky V; Olson TP; Fetterly K; Borlaug BA
Circ Heart Fail; 2015 May; 8(3):542-50. PubMed ID: 25857307
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Kramer T; Dumitrescu D; Gerhardt F; Orlova K; Ten Freyhaus H; Hellmich M; Baldus S; Rosenkranz S
Int J Cardiol; 2019 May; 283():152-158. PubMed ID: 30777406
[TBL] [Abstract][Full Text] [Related]
7. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
Bosch L; Lam CSP; Gong L; Chan SP; Sim D; Yeo D; Jaufeerally F; Leong KTG; Ong HY; Ng TP; Richards AM; Arslan F; Ling LH
Eur J Heart Fail; 2017 Dec; 19(12):1664-1671. PubMed ID: 28597497
[TBL] [Abstract][Full Text] [Related]
8. Dynamic nature of pulmonary artery systolic pressure in decompensated heart failure with preserved ejection fraction: role of functional mitral regurgitation.
Ennezat PV; Maréchaux S; Bouabdallaoui N; Le Jemtel TH
J Card Fail; 2013 Nov; 19(11):746-52. PubMed ID: 24263118
[TBL] [Abstract][Full Text] [Related]
9. The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension.
Ruan H; Zhang Y; Liu R; Yang X
Congenit Heart Dis; 2019 Jul; 14(4):645-650. PubMed ID: 31166081
[TBL] [Abstract][Full Text] [Related]
10. Fasudil improves short-term echocardiographic parameters of diastolic function in patients with type 2 diabetes with preserved left ventricular ejection fraction: a pilot study.
Guo R; Su Y; Yan J; Sun H; Wu J; Liu W; Xu Y
Heart Vessels; 2015 Jan; 30(1):89-97. PubMed ID: 24390764
[TBL] [Abstract][Full Text] [Related]
11. RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes.
Guazzi M; Dixon D; Labate V; Beussink-Nelson L; Bandera F; Cuttica MJ; Shah SJ
JACC Cardiovasc Imaging; 2017 Oct; 10(10 Pt B):1211-1221. PubMed ID: 28412423
[TBL] [Abstract][Full Text] [Related]
12. Effect of Rho kinase inhibitor fasudil on the expression ET-1 and NO in rats with hypoxic pulmonary hypertension.
Sun XZ; Li SY; Tian XY; Hong Z; Li JX
Clin Hemorheol Microcirc; 2019; 71(1):3-8. PubMed ID: 29660902
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary hypertension is related to peripheral endothelial dysfunction in heart failure with preserved ejection fraction.
Farrero M; Blanco I; Batlle M; Santiago E; Cardona M; Vidal B; Castel MA; Sitges M; Barbera JA; Perez-Villa F
Circ Heart Fail; 2014 Sep; 7(5):791-8. PubMed ID: 25047042
[TBL] [Abstract][Full Text] [Related]
14. Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.
Vanderpool RR; Saul M; Nouraie M; Gladwin MT; Simon MA
JAMA Cardiol; 2018 Apr; 3(4):298-306. PubMed ID: 29541759
[TBL] [Abstract][Full Text] [Related]
15. Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
Hanson SFL; Terry MH; Moretta DT; Power GG; Wilson SM; Alam F; Ahsan F; Blood AB; Giri PC
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):472-480. PubMed ID: 29756460
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis.
De Vecchis R; Cesaro A; Ariano C
Minerva Cardioangiol; 2018 Oct; 66(5):659-670. PubMed ID: 28398017
[TBL] [Abstract][Full Text] [Related]
17. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
Jiang BH; Tawara S; Abe K; Takaki A; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Feb; 49(2):85-9. PubMed ID: 17312448
[TBL] [Abstract][Full Text] [Related]
18. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.
Fujita H; Fukumoto Y; Saji K; Sugimura K; Demachi J; Nawata J; Shimokawa H
Heart Vessels; 2010 Mar; 25(2):144-9. PubMed ID: 20339976
[TBL] [Abstract][Full Text] [Related]
19. The Therapeutic Role of Rho Kinase Inhibitor, Fasudil, on Pulmonary Hypertension; a Systematic Review and Meta-Analysis.
Abedi F; Omidkhoda N; Arasteh O; Ghavami V; Hosseinzadeh H
Drug Res (Stuttg); 2023 Jan; 73(1):5-16. PubMed ID: 36216340
[TBL] [Abstract][Full Text] [Related]
20. Effects of fasudil on pulmonary hypertension in clinical practice.
Zhang Y; Wu S
Pulm Pharmacol Ther; 2017 Oct; 46():54-63. PubMed ID: 28782712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
